Abstract
The introduction of GP IIb-IIIa inhibitors is one of the most important developments in the treatment of acute coronary syndromes and acute complications of percutaneous coronary syndromes. To date, three parenteral GP IIb-IIIa inhibitors: abciximab, eptifibatide, and tirofiban have been approved for clinical use. These three agents have different pharmacological characteristics and associated pharmacodynamic and safety profiles. Currently, there is no standardized assay for measurement of inhibition of platelet aggregation, making direct comparisons qf pharmacodynamic properties of GP IIb-IIIa inhibitors impossible. The most common safety concerns with this class of agents are bleeding and thrombocytopenia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
